Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Chemo's hidden toll: new study tracks hair, skin, and nail changes in breast cancer patients

NCT ID NCT02530177

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 546 women with non-metastatic breast cancer to see how chemotherapy or endocrine therapy affects their hair, skin, and nails. Researchers will use clinical exams, photos, and questionnaires to track changes and identify who is most at risk. The goal is to better understand these side effects and improve how doctors prevent and treat them.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better predict and manage chemotherapy-related hair, skin, and nail side effects, improving quality of life for breast cancer patients.
What could go wrong
This is an observational study, not a treatment trial. It will not directly test any new therapy, and results may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 546 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2015

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

MSKCC clinics

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women newly diagnosed with non-metastatic breast cancer (stage 0-III, any receptor type) at the time of starting chemotherapy (dd-AC-T, CMF, Newer Combination Regimens) or endocrine therapy (tamoxifen, anastrozole, letrozole, exemestane) * Women ≥ 18 years at the time of enrollment into the study * Able to communicate in English and participate in the informed consent process * Able to comply with the follow-up visits, assessments, answering questionnaires Exclusion Criteria: * Metastatic breast cancer * Follow-up care/visits not scheduled at MSKCC * Any current alopecia especially due to an active scalp and/or hair disorder (e.g. alopecia areata), or a pre-existing condition with sequelae (e.g. scarring alopecia) * Currently active or uncontrolled medical condition \[e.g. thyroid disorder, auto-immune connective tissue disease (e.g. SLE), BMT complications (GVHD)\] or medication intake (e.g. HRT), affecting scalp hair * Prior systemic treatment for any malignancy * Active secondary cancer requiring cytotoxic chemotherapy * Planned (or a history of) radiation therapy to the head * Vulnerable populations \[e.g. decisionally impaired (cognitive, psychiatric), terminally ill, prisoners\], or patients who, in the opinion of the investigator have a condition that precludes their ability to provide an informed consent * Men Volunteer Inclusion Criteria: * Post menopausal women, with menopausal status defined as (per self report): * Bilateral salpingo-oophorectomy independent of age * If natural menopause, age ≥ 50 with cessation of menses for at least 12 months * Or premenopausal women with premenopausal status defined as \<53 years of age with no cessation of menses * Able to communicate in English and participate in the informed consent process * Able to comply with the baseline assessments and answering questionnaires * Women \>/= 18 years at the time of enrollment into the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non metastatic breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.